Validation and verification of the OPI 2.0 System

QR Code

Validation and verification of the OPI 2.0 System

Richard Abelson1,2, Keith J Lane3, John Rodriguez3, Patrick Johnston3, Endri Angjeli3, George Ousler3, Douglas Montgomery11School of Computing, Informatics, and Decision Systems Engineering, Arizona State University, Tempe, AZ, 2Statistics and Data Corporation, Tempe, AZ, 3Ora, Inc, Andover, MA, USA...

Full description

Saved in:

Bibliographic Details
Main Authors:	Abelson R, Lane KJ, Rodriguez J, Johnston P, Angjeli E, Ousler G, Montgomery D
Format:	article
Language:	EN
Published:	Dove Medical Press 2012
Subjects:	Ophthalmology RE1-994
Online Access:	https://doaj.org/article/7c507a53b602492982bb9452c13b9e8a
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Measurement of ocular surface protection under natural blink conditions
by: Abelson R, et al.
Published: (2011)

A single-center study evaluating the effect of the controlled adverse environment (CAEsm) model on tear film stability
by: Abelson R, et al.
Published: (2012)

The interblink interval in normal and dry eye subjects
by: Johnston PR, et al.
Published: (2013)

Investigation of extended blinks and interblink intervals in subjects with and without dry eye
by: Rodriguez JD, et al.
Published: (2013)

Automated grading system for evaluation of ocular redness associated with dry eye
by: Rodriguez JD, et al.
Published: (2013)

Blink patterns and lid-contact times in dry-eye and normal subjects
by: Ousler GW 3rd, et al.
Published: (2014)

Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy
by: Gomes PJ, et al.
Published: (2013)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
by: Baiza-Dur&aacute;n LM, et al.
Published: (2012)

Cone photoreceptor macular function and recovery after photostress in early non-exudative age-related macular degeneration
by: Rodriguez JD, et al.
Published: (2018)

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
by: Anne J Lee, et al.
Published: (2008)

Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
by: Coffey MJ, et al.
Published: (2013)

Evaluation and validity of the Danish version of the Adult Strabismus Questionnaire AS-20
by: Ali N, et al.
Published: (2015)

Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
by: Sosne G, et al.
Published: (2015)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
by: Schnober D, et al.
Published: (2015)

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
by: Arthur B Epstein, et al.
Published: (2009)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
by: Inoue K, et al.
Published: (2015)

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily
by: Moisseiev E, et al.
Published: (2013)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
by: Kanamoto T, et al.
Published: (2012)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
by: Abayomi B Ogundele, et al.
Published: (2010)

Efficacy and safety of 0.5% levobupivacaine versus 0.5% bupivacaine for peribulbar anesthesia
by: Pacella E, et al.
Published: (2013)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
by: Inoue K, et al.
Published: (2012)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
by: Douglas J Rhee, et al.
Published: (2008)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
by: Moataz E Gheith, et al.
Published: (2008)

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
by: Bucci FA Jr, et al.
Published: (2015)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
by: Chang-Lin J-E, et al.
Published: (2011)

Tetracaine 0.5% eyedrops with or without lidocaine 2% gel in topical anesthesia for cataract surgery
by: Anthoula T Tsoumani, et al.
Published: (2010)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
by: Shimizu Y, et al.
Published: (2015)

Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye
by: Meerovitch K, et al.
Published: (2013)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
by: Mizoguchi T, et al.
Published: (2012)

Corneal topographic changes following trans-conjunctival 20 gauge sutureless vitrectomy (TC20V)
by: Abdel Alim Mohamed A, et al.
Published: (2012)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
by: Michael J Miyashiro, et al.
Published: (2010)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
by: Costa VP, et al.
Published: (2012)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
by: Yelda Buyru &Ouml;zkurt, et al.
Published: (2009)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
by: Myers JS, et al.
Published: (2014)

An evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye
by: Ousler III G, et al.
Published: (2015)

Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension
by: Sharma S, et al.
Published: (2015)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
by: Nicholas P Bell, et al.
Published: (2010)

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
by: Inoue K, et al.
Published: (2014)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
by: David A Godfrey, et al.
Published: (2009)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
by: Abayomi B Ogundele, et al.
Published: (2010)